Irbesartan: A review of its use in hypertension and in the management of diabetic nephropathy

Drugs

Volumn 64, Issue 9, 2004, Pages 999-1028

  Croom, Katherine F ^a   Curran, Monique P ^a   Goa, Karen L ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Diabetic nephropathy; Hypertension; Irbesartan; Pharmacodynamics; Pharmacokinetics; Therapeutic use; Type 2 diabetes mellitus

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALUMINUM HYDROXIDE; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FLUCONAZOLE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; MAGNESIUM; NIFEDIPINE; OLMESARTAN; PLACEBO; SIMVASTATIN; TOLBUTAMIDE; VALSARTAN; WARFARIN;

ADD ON THERAPY; AGING; ANKLE EDEMA; ANXIETY DISORDER; AREA UNDER THE CURVE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; COUGHING; DIABETIC NEUROPATHY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RESPONSE; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; HEADACHE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE HYPERTROPHY; HEART REPOLARIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY CLEARANCE; MICROALBUMINURIA; MONOTHERAPY; MUSCULOSKELETAL INJURY; NERVOUSNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPERTENSION; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMICS; PHARMACOLOGICAL BLOCKING; PROTEINURIA; RECEPTOR BLOCKING; REVIEW; SIDE EFFECT; TACHYCARDIA; THORAX PAIN;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS; TETRAZOLES;

EID: 2342577439     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464090-00011     Document Type: Review

References (148)

1. Gillis JC Markham A. Irbesartan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997 Dec; 54 (6): 885-902
2. Markham A, Spencer CM, Jarvis B. Irbesartan: an update of its use in cardiovascular disorders. Drugs 2000 May; 59 (5): 1187-206
3. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001 Feb 13; 103 (6): 904-12
4. Ellis ML, Patterson JH. A new class of antihypertensive therapy: angiotensin II receptor antagonists. Pharmacotherapy 1996 Sep-Oct; 16 (5): 849-60
5. White M, Racine N, Ducharme A, et al. Therapeutic potential of angiotensin II receptor antagonists. Expert Opin Invest Drugs 2001 Sep; 10 (9): 1687-701
6. Rodgers JE, Patterson JH. Angiotensin II-receptor blockers: Clinical relevance and therapeutic role [published erratum appears in Am J Health Syst Pharm 2001 Sep 1; 58(17): 1168]. Am J Health Syst Pharm 2001 Apr; 58 (8): 671-83
7. Belz GG, Butzer R, Kober S, et al. Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay. Clin Pharmacol Ther 1999 Oct; 66 (4): 367-73
8. Mazzolai L, Maillard M, Rossat J, et al. Angiotensin II receptor blockade in normotensive subjects: a direct comparison of three AT1 receptor antagonists. Hypertension 1999 Mar; 33 (3): 850-5
9. Ribstein J, Picard A, Armagnac C, et al. Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men. J Cardiovasc Pharmacol 2001 Apr; 37 (4): 449-60
10. Burnier M, Hagman M, Nussberger J, et al. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995 Apr; 25 (4 Pt 1): 602-9
11. Schmitt F, Martinez F, Brillet G, et al. Acute renal effects of AT1-receptor blockade after exogenous angiotensin II infusion in healthy subjects. J Cardiovasc Pharmacol 1998 Feb; 31 (2): 314-21
12. Marino MR, Langenbacher K, Ford NF, et al. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pharmacol 1998 Mar; 38 (3): 246-55
13. Pechère-Bertschi A, Nussberger J, Decosterd L, et al. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients. J Hypertens 1998 Mar; 16 (3): 385-93
14. Sica DA, Marino MR, Hammett JL, et al. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. Clin Pharmacol Ther 1997 Dec; 62 (6): 610-8
15. Butzer R, Belz GG, Kober S, et al. Irbesartan results in more complete blockade of human adrenal AT1-receptor mediated effects than does candesartan cilexetil as evidenced by blunted plasma aldosterone levels [abstract no. P3.225]. J Hypertens 2000 Jun; 18 Suppl. 2: S209
16. Kober S, Butzer R, Langguth P, et al. Extent and duration of angiotensin II antagonistic activity of irbesartan and candesartan cilexetil [abstract no. A105]. Am J Hypertension 2000 Apr; 13 (4 Pt 2): 150A
17. Belz GG, Butzer R, Kober S, et al. Irbesartan results in more complete blockade of human renal AT1-receptor mediated effects than does candesartan cilexetil as evidenced by higher plasma renin levels [abstract no. A106]. Am J Hypertens 2000 Apr; 13 (4 Pt 2): 151A
18. McIntyre M, MacFadyen RJ, Meredith PA, et al. Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men. J Cardiovasc Pharmacol 1996 Jul; 28(1): 101-6
19. Azizi M, Bissery A, Bura-Riviere A, et al. Dual renin-angiotensin system blockade restores blood pressure-renin dependency in individuals with low renin concentrations. J Hypertens 2003 Oct; 21 (10): 1887-95
20. Lauten WB, Khan QA, Rajagopalan S. et al. Usefulness of quinapril and irbesartan to improve the anti-inflammatory response of atorvastatin and aspirin in patients with coronary artery disease. Am J Cardiol 2003 May 1; 91: 1116-9
21. Burnier M, Pechere-Bertschi A, Nussberger J, et al. Studies of the renal effects of angiotensin II receptor blockade: the confounding factor of acute water loading on the action of vasoactive systems. Am J Kidney Dis 1995 Jul; 26 (1): 108-15
22. Vachharajani NN, Shyu WC Chando TJ, et al. Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. J Clin Pharmacol 1998 Aug; 38 (8): 702-7
23. Chando TJ, Everett DW, Kahle AD, et al. Biotransformation of irbesartan in man. Drug Metab Dispos 1998 May; 26 (5): 408-17
24. Vachharajani NN, Shyu WC, Smith RA, et al. The effects of age and gender on the pharmacokinetics of irbesartan. Br J Clin Pharmacol 1998 Dec; 46 (6): 611-3
25. Marino MR, Langenbacher KM, Raymond RH, et al. Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis. J Clin Pharmacol 1998 Apr; 38 (4): 347-56
26. Kostis JB, Vachharajani NN, Hadjilambris OW, et al. The pharmacokinetics and pharmacodynamics of irbesartan in heart failure. J Clin Pharmacol 2001 Sep; 41 (9): 935-42
27. Vachharajani N, Shyu WC, Mantha S, et al. Lack of food effect on the oral bioavailability of irbesartan [abstract no. 60]. J Clin Pharmacology 1997 Sep; 37 (9): 872
28. Morsing P, Adler G, Brandt-Eliasson U, et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension 1999 Jun; 33 (6): 1406-13
29. Ruilope L. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist J Hypertens 1997 Dec; 15 Suppl. 7: S15-20
30. Perrier L, Bourrié M, Marti E, et al. In vitro N-glucuronidation of SR 474346 (BMS 186295), a new AT1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions. J Pharmacol Exp Ther 1994 Oct; 271 (1): 91-9
31. Bourrié M, Meunier V, Berger Y, et al. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes. Drug Metab Dispos 1999 Feb; 27 (2): 288-96
32. Marino MR, Vachharajani NN. Drug interactions with irbesartan. Clin Pharmacokinet 2001; 40 (8): 605-14
33. Marino MR, Hammett JL, Ferreira I, et al. Effect of nifedipine on the steady-state pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Cardiovasc Pharmacol Ther 1998 Apr; 3 (2): 111-8
34. Mangold B, Gielsdorf W, Marino MR. Irbesartan does not affect the steady-state pharmacodynamics and pharmacokinetics of warfarin. Eur J Clin Pharmacol 1999 Oct; 55 (8): 593-8
35. Marino MR, Vachharajani NN, Hadjilambris OW. Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects. J Clin Pharmacol 2000 Aug; 40 (8): 875-9
36. Marino MR, Langenbacher KM, Mangold B, et al. Lack of drug interactions with irbesartan: a summary of five pharmacokinetic studies [abstract no. P31.096]. J Hypertens 1998 Jun; 16 Suppl. 2: S248
37. Kovacs SJ, Wilton JH, Blum RA. Steady state (SS) pharmacokinetics (PK) of irbesartan alone and in combination with fluconazole (F) [abstract no. PI-59]. Clin Pharmacol Ther 1999 Feb; 65 (2): 132
38. Marino MR, Langenbacher KM, Ford NF, et al. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of the angiotensin II blocker irbesartan. Clin Drug Invest 1997 Nov; 14 (5): 383-91
39. Escolar M, Lopez de Ocariz A, Simon M, et al. Effects of antacids on irbesartan pharmacokinetics [abstract no. PC-9]. Meth Find Exp Clin Pharmacol 1998; 20 Suppl. A: 53
40. Marino MR, Hammett JL, Ferreira I, et al. Effect of irbesartan on the steady-state pharmacokinetics of digoxin in healthy male subjects [abstract no. P-278E]. ASHP Midyear Clinical Meeting 1998; 33: 2301
41. Lacourcière Y. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged ≥65 years with mild to moderate hypertension. Clin Ther 2000 Oct; 22 (10): 1213-24
42. Mimran A, Ruilope L, Kerwin L, et al. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens 1998 Mar; 12 (3): 203-8
43. Coca A, Calvo C, Garcia-Puig J, et al. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension as assessed by ambulatory blood pressure monitoring: the MAPAVEL study. Clin Ther 2002 Jan; 24 (1): 126-38
44. Chiou K-R, Chen C-H, Ding PY-A, et al. Randomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension. Chin Med J (Taipei) 2000 May; 63 (5): 368-76
45. Neutel J, Germino W, Smith D, et al. The antihypertensive efficacy and safety of irbesartan compared with amlodipine for the treatment of mild-to-moderate hypertension [abstract no. D068]. Am J Hypertens 1999 Apr; 12 (4 Pt 2): 128A plus poster
46. Mancia G, Korlipara K, van Rossum P, et al. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002 Apr; 7 (2): 135-42
47. Kassler-Taub K, Littlejohn T, Elliott W, et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Irbesartan/ Losartan Study Investigators [published erratum appears in Am J Hypertension 1998 Jun; 11 (6 Pt 1): 736]. Am J Hypertens 1998; 11 (4 Pt 1): 445-53
48. Oparil S, Guthrie R, Lewin AJ, et al. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan: Irbesartan/Losartan Study Group Investigators. Clin Ther 1998 May-Jun; 20 (3): 398-409
49. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension [published erratum appears in J Clin Hypertens (Greenwich) 2001 Nov-Dec; 3 (6): 395]. J Clin Hypertens (Greenwich) 2001 Sep-Oct; 3 (5): 283-91, 318
50. Stumpe KO, Haworth D, Hoglund C, et al. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. Blood Press 1998 Jan; 7 (1): 31-7
51. Fogari R, Ambrosoli S, Corradi L, et al. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring: Irbesartan Multicenter Investigators' Group. J Hypertens. 1997 Dec; 15 (12 Pt 1): 1511-8
52. Pool JL, Guthrie RM, Littlejohn III TW, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998 Apr; 11 (4 Pt 1): 462-70
53. Guthrie R, Saini R, Herman T, et al. Efficacy and tolerability of irbesartan, an angiotensin II receptor antagonist, in primary hypertension: a double-blind, placebo-controlled, dose-titration study. Multicentre Investigators. Clin Drug Invest 1998 Mar; 15 (3): 217-27
54. Reeves RA, Lin C-S, Kassler-Taub K, et al. Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension 1998 Jun; 31 (6): 1311-6
55. Weber M, Saini R, Kassler-Taub K, et al. Irbesartan combined with low-dose hydrochlorothiazide for mild-to-moderate hypertension [abstract no. P16.27]. J Hypertens 1998 Jun; 16 Suppl. 2: S129
56. Howe P, Phillips P, Saini R, et al. The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Clin Exper Hypertension 1999 Nov; 21(8): 1373-96
57. Rosenstock J, Rossi L, Lin CS, et al. The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. J Clin Pharm Ther 1998 Dec; 23 (6): 433-40
58. Weir MR, Tolchin N, Toth P, et al. Addition of hydrochlorothiazide to irbesartan produces further dose-related reductions in blood pressure within two weeks [abstract no. P16.34]. J Hypertens 1998 Jun; 16 Suppl. 2: S130
59. Kochar M, Guthrie R, Triscari J, et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999; 12 (8 Pt 1): 797-805
60. Larochelle P, Flack JM, Marbury TC, et al. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension: Irbesartan Multicenter Investigators. Am J Cardiol 1997 Dec 15; 80 (12): 1613-5
61. Littlejohn III T, Saini R, Kassler-Taub K, et al. Long-term safety and antihypertensive efficacy of irbesartan: pooled results of five open-label studies. Clin Exper Hypertension 1999 Nov; 21 (8): 1273-95
62. Raskin P, Guthrie R, Flack JM, et al. The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. J Hum Hypertens 1999 Oct; 13 (10): 683-7
63. Bays HE, Park JS, Reilly K, et al. Irbesartan safety and effectiveness; a postmarketing surveillance study [abstract no. D039]. AST investigators. Am J Hypertens 1999; 12 (4 Pt 2): 120A
64. Kurland L, Melhus H, Karlsson J, et al. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001 Oct; 19: 1783-7
65. Kurland L, Melhus H, Karlsson J, et al. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA) trial. Am J Hypertens 2002; 15 (5): 389-93
66. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002 Nov-Dec; 4 (6): 393-404
67. Coca A, Calvo C, Sobrino J, et al. Once-daily fixed-combination irbesartan 300mg/hydrochlorothiazide 25mg and circadian blood pressure profile in patients with essential hypertension. Clin Ther 2003 Nov; 25 (11): 2849-64
68. Kannel WB, Levy D, Cupples LA. Left ventricular hypertrophy and risk of cardiac failure: insights from the Framingham Study. J Cardiovasc Pharmacol 1987; 10 Suppl. 6: S13540
69. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990 May 31; 322 (22): 1561-6
70. McLenachan JM, Henderson E, Morris KI, et al. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 1987 Sep 24; 317 (13): 787-92
71. Villatico Campbell S, Rizzo V, Di Maio F, et al. Comparison of irbesartan versus enalapril on left ventricular mass and function in stage I-II hypertensives [abstract no. P.70]. J Hypertens 1998 Jun; 16 Suppl. 2: S18
72. Feraco E. Therapeutic effects of irbesartan in left ventricular hypertrophy [abstract no. D019]. Am J Hypertens 1999 Apr; 12 (4 Pt 2): 115A
73. Malmqvist K, Kahan T, Edner M, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001 Jun; 19 (6): 1167-76
74. Gaudio C, Ferri FM, Giovannini M, et al. Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. J Cardiovasc Pharmacol 2003 Nov; 42 (5): 622-8
75. Malmqvist K, Kahan T, Edner M, et al. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA). Am J Cardiol 2002 Nov 15; 90 (10): 1107-12
76. Pohl M, Cooper M, Ulrey J, et al. Safety and efficacy of irbesartan in hypertensive patients with type II diabetes and proteinuria [abstract no. D4]. Am J Hypertens 1997 Apr; 10 (Pt 2): 105
77. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001 Sep 20; 345 (12): 870-8
78. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 Sep 20; 345 (12): 851-60
79. Sasso FC, Carbonara O, Persico M, et al. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study. Diabetes Care 2002 Nov; 25 (11): 1909-13
80. Rossing K, Christensen PK, Andersen S, et al. Comparative effects of irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study. Diabetes Care 2003 Mar; 26 (3): 569-74
81. Andersen S, Bröchner-Mortensen J, Parving H-H. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria: Irbesartan in patients with type 2 diabetes and microalbuminuria Study Group. Diabetes Care 2003 Dec; 26 (12): 3296-302
82. Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy: Collaborative Study Group. Ann Intern Med 2003 Apr 1; 138 (7): 542-9
83. Palmer AJ, Annemans L, Roze S, et al. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings. Nephrol Dial Transplant 2003 Oct; 18 (10): 2059-66
84. Rodby RA, Chiou C-F, Borenstein J, et al. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin Ther 2003; 25 (7): 2102-19
85. Coyle D, Rodby RA. Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada. Can J Cardiol 2004 Jan; 20 (1): 71-9
86. Koch H, Pirk O, Schöffski, et al. Treatment of hypertensive type 2 diabetics (t2d) with irbesartan (Irb) is cost-saving due to prevented or delayed end-stage renal disease [abstract no. 22]. Int J Clin Pharm and Ther 2003; 41 (11): 537-8
87. Simon TA, Gelarden RT, Freitag SA, et al. Safety of irbesartan in the treatment of mild to moderate systemic hypertension. Am J Cardiol 1998 Jul; 82 (2): 179-82
88. Sanofi Pharma, Bristol-Myers Squibb SNC. Aprovel 75mg tablets; Aprovel 150mg tablets; Aprovel 300mg tablets: summary of product characteristics. Paris: Sanofi Pharma, Bristol-Myers Squibb SNC, 2002 Jun
89. Bristol-Myers Squibb Company, Sanofi-Synthelabo. Avalide® (irbesartan-hydrochlorothiazide) tablets: prescribing information. New York: Bristol-Myers Squibb Sanofi-Synthelabo Partnership, 2002 Apr
90. Bristol-Myers Squibb Company, Sanofi-Synthelabo. Avapro® (irbesartan) tablets: prescribing information. New York: Bristol-Myers Squibb Sanofi-Synthelabo Partnership, 2002 Aug
91. Sweetman SC. Martindale: the complete drug reference. 33rd ed. London: Pharmaceutical Press, 2002
92. Sanofi-Synthelabo Australia Pty Limited. Product information: Karvea® (irbesartan) [online]. Available from URL: http:// www.sanofi-synthelabo.co.au [Accessed 2004 Mar 23]
93. Doctor's Guide. Health Canada approves Avapro (irbesartan) for the treatment of diabetic renal disease [online]. Available from URL: http://www.pslgroup.com/dg [Accessed 2004 Mar 23]
94. World Health Organization. The world health report 2002: risks to health 2002. Quantifying Selected Major Risks to health. Geneva: World Health Organization, 2002: 47-96
95. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994 Apr; 50 (2): 272-98
96. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/ International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003 Nov; 21 (11): 1983-92
97. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003 Jun; 21 (6): 1011-53
98. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [published erratum appears in JAMA 2003 Jul 9; 290(2): 197]. JAMA 2003 May 21; 289 (19): 2560-72
99. Parati G, Pomidossi G, Albini F, et al. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 1987 Feb; 5 (1): 93-8
100. Frattola A, Parati G, Cuspidi C, et al. Prognostic value of 24-hour blood pressure variability. J Hypertens 1993 Oct; 11 (10): 1133-7
101. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23; 359 (9311): 995-1003
102. Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23; 359 (9311): 1004-10
103. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Med 1997; 14 Suppl. 5: 1-85
104. Ritz E, Rychlik I, Locatelli F, et al. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999 Nov; 34 (5): 795-808
105. United States Renal Data System. 2001 Annual Data Report: atlas of end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, 2001. Chapter 1: 37-52
106. Parving HH, Andersen AR, Smidt UM, et al. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983 May 28; 1 (8335): 1175-9
107. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Ed) 1982 Sep 11; 285 (6343): 685-8
108. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group [published erratum appears in Br Med J 1999 Jan 2; 318 (7175): 29]. Br Med J 1998 Sep 12; 317 (7160): 703-13
109. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators [published erratum appears in Lancet 2000 Sep 2; 356 (9232): 860]. Lancet 2000 Jan 22; 355 (9200): 253-9
110. Estacio RO, Jeffers BW, Gifford N, et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes mellitus. Diabetes Care 2000 Apr; 23 Suppl. 2: B54-64
111. Salvetti A, Mattei P, Sudano I. Renal protection and antihypertensive drugs: current status. Drugs 1999 May; 57 (5): 665-93
112. Parving HH, Tarnow L, Rossing P. Renal protection in diabetes: an emerging role for calcium antagonists. J Hypertens 1996 Nov; 14 Suppl. 4: S21-5
113. Toto R. Angiotensin II subtype 1 receptor blockers and renal function. Arch Intern Med 2001 Jun 25; 161 (12): 1492-9
114. Ramsay LE, Williams B, Johnston GD, et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999 Sep 4; 319 (7210): 630-5
115. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Disease 2000 Sep; 36 (3): 646-61
116. Meltzer S, Leiter L, Daneman D, et al. 1998 clinical practice guidelines for the management of diabetes in Canada: Canadian Diabetes Association. CMAJ 1998; 159 Suppl. 8: 1-29
117. Arauz-Pacheco C, Parrott MA, Raskin P, et al. Treatment of hypertension in adults with diabetes. American Diabetes Association. Diabetes Care 2003 Jan; 26 Suppl. 1: S80-2
118. Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. BMJ 2000 Mar 11; 320 (7236): 705-8
119. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998 Jul 18; 352 (9123): 213-9
120. Ruilope L. RAS blockade: new possibilities in the treatment of complications of diabetes. Heart 2000 Sep; 84 Suppl. 1: i32-4, discussion i50
121. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group [published erratum appears in N Engl J Med 1993 Jan 13; 330 (2): 152]. N Engl J Med 1993 Nov 11; 329 (20): 1456-62
122. Viberti G, Mogensen CE, Groop LC, et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria: European Microalbuminuria Captopril Study Group. JAMA 1994 Jan 26; 271 (4): 275-9
123. Mogensen CE, Neldam S, Tikkanen J, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan And Lisinopril Microalbuminuria (CALM) study. BMJ 2000 Dec 9; 321 (7274): 1440-4
124. Agardh CD, Garcia-Puig J, Charbonnel B, et al. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996 Mar; 10 (3): 185-92
125. Lacourcière Y, Belanger A, GodinC, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000 Aug; 58 (2): 762-9
126. Schnack C, Hoffmann W, Hopmeier P, et al. Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. Diabetologia 1996 Dec; 39 (12): 1611-6
127. Nielsen FS, Rossing P, Gall MA, et al. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997 Jul; 46 (7): 1182-8
128. Bakris GL, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996 Nov; 50 (5): 1641-50
129. Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996 Feb 12; 156 (3): 286-9
130. Gansevoort RT, Sluiter WJ, Hemmelder MH, et al. Antiprotein-uric effect of blood-pressure-lowering agents: a meta- analysis of comparative trials. Nephrol Dial Transplant 1995 Nov; 10 (11): 1963-74
131. Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993 Jan 15; 118 (2): 129-38
132. Weidmann P, Schneider M, Bohlen L. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis. Nephrol Dial Transplant 1995 Oct; 10 Suppl 9: 39-45
133. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 Sep 20; 345 (12): 861-9
134. Muirhead N, Feagan BF, Mahon J, et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial. Curr Ther Res 1999 Dec; 60: 650-60
135. Viberti G, Wheeldon NM, Microalbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood-pressure-independent effect. Circulation 2002; 106: 672-8
136. Molitch ME, De Fronzo RA, Franz MJ, et al. Diabetic nephropathy: American Diabetes Association. Diabetes Care 2003 Jan; 26 Suppl. 1: S94-8
137. Working Party of the International Diabetes Federation (Europ-ean Region). Hypertension in people with type 2 diabetes: knowledge-based diabetes-specific guidelines. Diabet Med 2003 Dec; 20 (12): 972-87
138. Pylypchuk GB. ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother 1998 Oct; 32 (10): 1060-6
139. Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999 Jul; 21 (1): 23-33
140. LacourcièreY, Brunner H, Irwin R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough: Losartan Cough Study Group. J Hypertens 1994 Dec; 12 (12): 1387-93
141. Benz J, Oshrain C, Henry D, et al. Valsartan, a new angiotensin II receptor antagonist a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997 Feb; 37 (2): 101-7
142. Rossing K, Christensen PK, Jensen BR, et al. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002 Jan; 25 (1): 95-100
143. Jacobsen P, Andersen S, Rossing K, et al. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 2002 Jun; 17 (6): 1019-24
144. Jacobsen P, Andersen S, Rossing K, et al. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003 May; 63 (5): 1874-80
145. Jacobsen P, Andersen S, Jensen BR, et al. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003; 14: 992-9
146. Rossing K, Jacobsen P, Pietraszek L, et al. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy. Diabetes Care 2003; 26 (8): 2268-74
147. Cannon CP. Innovative directions in th future role of antiplatelet agents. In: Califf RM, Topol EJ, Mehta SR et al. Therapeutic Challenges in the Treatment of Cardiovascular Disease: issue and answers [online]. Available from URL: http:// www.medscape.com/viewprogram/2891_pnt [Accessed 2004 Mar 9]
148. Bannerjee P, Clark AL, Cleland JGF. Diastolic heart failure: a difficult problem in the elderly. Am J Geriatr Cardiol 2004; 13 (1): 16-21